Timing note: The scheduled event date is July 23, 2026. Since today is also July 23, this is a same-day, pre-release preview, using information available through the July 22 market close.
West Pharmaceutical Services enters 2Q26 with a strong underlying growth setup—particularly in high-value product (HVP) components, biologics, GLP-1-related demand, Annex 1-driven conversions, and operating leverage. Its 1Q print materially exceeded guidance, prompting a full-year revenue and EPS increase.
However, the dominant issue for this quarter is the May cybersecurity attack. West disclosed that the incident temporarily disrupted global operations, including shipping, receiving, and manufacturing, while system restoration was still in progress as of May 11. Because the 2Q outlook was issued on April 23—before the May 4 intrusion—investors need clarity on whether the original quarterly and full-year guidance absorbed lost production, shipment delays, recovery costs, customer-service issues, or any insurance recoveries.
Bottom line: A simple “beat” may not be enough after the stock’s strong run. The market will likely focus on (1) the cyberattack’s financial and operational effect, (2) whether full-year guidance remains intact or rises, and (3) proof that HVP/biologics momentum continued despite the disruption.
| Metric | Company 2Q26 outlook issued April 23 | Implied growth |
|---|---|---|
| Net sales | $830M–$850M | +8.3% to +10.9% reported |
| Organic sales growth | — | +7.0% to +9.6% |
| Adjusted diluted EPS | $2.05–$2.12 | +11.4% to +15.2% |
For full-year 2026, West’s most recent guidance is:
| Metric | FY26 guidance |
|---|---|
| Net sales | $3.295B–$3.350B |
| Organic sales growth | +7% to +9% |
| Adjusted diluted EPS | $8.40–$8.75 |
| Capital expenditures | $250M–$275M |
The midpoint of quarterly guidance is $840M revenue and $2.09 adjusted EPS. Importantly, 1Q adjusted EPS of $2.13 landed roughly 45% above the midpoint of the company’s original 1Q guide, so investors have seen that management can be conservative. The question now is whether cyber disruption offsets that usual upside.
In 1Q, HVP Components delivered 22.6% organic growth and represented 48% of company sales. The growth was not solely GLP-1 dependent:
The quality of this growth matters. Greater HVP penetration supports pricing, gross margin, and plant absorption—not simply revenue volume. A sustained low-to-mid-teens full-year organic HVP component growth trajectory would reinforce the view that West is benefiting from several durable demand drivers simultaneously.
West expects Annex 1-related conversion and broader HVP upgrades to contribute approximately 200 basis points of company growth in 2026, with a multiyear runway. Management has identified at least 6 billion units that could be candidates for conversion.
This is strategically attractive because it upgrades existing component demand into more valuable products and processes; the volume may not need to change for revenue and margins to improve. Investors should look for updated project counts, conversion timing, commercial launches, and evidence that the opportunity is expanding beyond Europe into the United States and Asia.
1Q adjusted operating margin expanded 350 basis points year over year to 21.4%, driven by HVP mix, pricing, better plant utilization, and leverage of overhead. Management had indicated that:
That makes gross margin, adjusted operating margin, and commentary around plant productivity especially important. A margin miss would matter more than a small revenue variance, since it could signal cyber-related inefficiency, recovery expense, unfavorable product mix, or a slower-than-expected capacity ramp.
West disclosed on May 11 that it had experienced a material cybersecurity incident detected on May 4, 2026. The company stated that data had been exfiltrated, certain systems encrypted, and that it had proactively taken systems offline. While core enterprise systems and critical shipping, receiving, and manufacturing processes had restarted at some facilities, full restoration had not yet been finalized at that point.
Did customer inventory or backlog absorb the disruption?
Cost impact
Insurance coverage, deductibles, and timing of recoveries.
Current operational status
Whether the incident altered customer behavior or qualification schedules.
Guidance implications
The most favorable outcome is a message that the disruption was brief, revenue largely shifted rather than lost, and incremental costs are contained. The less favorable outcome is an unquantified or open-ended recovery timeline, especially if it affects the company’s high-utilization HVP network.
West had expected the sale of its SmartDose 3.5mL on-body delivery system business and associated facilities to AbbVie to close around midyear. The business generated $55M of revenue in 2H25, creating a known comparison headwind once sold.
Key questions:
The company stressed in 1Q that the non-SmartDose delivery-device business was also performing well, led by SelfDose and Daikyo Crystal Zenith. Continued strength there would help investors view the divestiture as portfolio optimization rather than a loss of growth.
West Vantage—formerly Contract-Manufactured Products—grew 6.2% organically in 1Q. The segment is expected to face a 2H headwind from the roll-off of a continuous glucose monitoring contract, estimated at roughly $40M for the second half.
Management expects:
For 2Q, investors should assess whether new Dublin activity and customer backfill are proceeding as expected. This is less important than HVP components in the near term, but it matters to the 2027 earnings algorithm.
CEO Eric Green previously indicated that his successor was expected to be appointed in 2H26. A leadership announcement is possible, although not necessary for the quarter to work. Investors will want evidence of continuity in the company’s HVP-focused strategy, manufacturing execution, capital allocation, and customer relationships.
On July 14, West renewed key technology-exchange, cross-license, and distributorship agreements with Daikyo Seiko, in which West holds a 49% stake. The agreements have 10-year terms and are substantially similar to prior arrangements. This is not likely to drive the 2Q result, but it supports continuity around product technology, distribution, and the Daikyo relationship—particularly relevant to Crystal Zenith and premium injectable solutions.
WST closed at $358.45 on July 22, up approximately:
The stock’s April 23 reaction was sharp, rising from $274.41 on April 22 to $309.70 on April 23 after the strong 1Q result and raised outlook. The subsequent appreciation means expectations are likely higher than the formal company guide alone suggests.
Therefore, the setup looks less like a low-bar quarter and more like a credibility-and-durability test:
West’s core investment case remains compelling: premium injectable-component demand, biologics penetration, GLP-1 exposure, regulatory-driven HVP conversion, and margin expansion from mix and manufacturing productivity. Yet 2Q26 is unusually binary because the company’s formal outlook predates the May cyberattack.
For this report, the most important result is not simply whether West exceeds $830M–$850M of revenue and $2.05–$2.12 of adjusted EPS. It is whether management can demonstrate that the cyber incident was operationally contained and that the company’s raised full-year growth and margin outlook remains durable.
Sources reviewed: West 1Q26 earnings release and earnings-call transcript dated April 23, 2026; West May 11, 2026 Form 8-K and cyberattack update; West July 14, 2026 Form 8-K regarding Daikyo agreements; WST historical closing-price data through July 22, 2026.